Fig. 7

In vivo efficacy of PLX038A + rucaparib in SEC PDXs. Mice with measurable tumors were randomized to one of four groups: control (red), PLX038A every two weeks at 15 µmol/kg IP injection (blue), rucaparib 150 mg/kg daily gavage (green), or combination (purple) for 8 weeks, followed by one week of observation. Tumor size was assessed by weekly transabdominal ultrasound and normalized to the day zero starting size. P53 status by IHC is indicated as a wildtype (wt) or aberrant/mutated (mut) pattern. Tumor size trajectories are the average estimates computed from the statistical linear mixed effects models, relative to the arm-specific baseline estimate. Shading indicates 95% confidence intervals. The P values are provided in Supplementary Table 3. The number of mice under observation at each time point for each arm is indicated below the x-axis as a function of time, where text color indicates drug arm